NTLA

9.9904.94%
BS

Birgit Schultes

Executive VP & Chief Scientific Officer

Dr. Birgit Schultes, Ph.D., is Executive Vice President & Chief Scientific Officer of Intellia Therapeutics, Inc. from January 13, 2025 and served as its Head of Cell Therapies from November 2021 and served as its Senior VP from November 2021 to January 13, 2025. She was Vice President of Research of Twin Butte Energy Ltd. She has experience in the biotechnology and pharmaceutical industry, she brings deep immunology and cell therapy expertise to Intellia. She manages a multidisciplinary team focused on ex vivo applications of CRISPR/Cas9 to generate novel cell therapies for oncology and autoimmune indications. Prior to joining Intellia, she served as Senior Director, In Vivo and Exploratory Immunology, at Unum Therapeutics (now Cogent Biosciences, Inc.), where she was responsible for its in vivo team and leading its exploratory immunology efforts. Earlier in her career, she held a variety of translational research roles in biology and immunology at Momenta Pharmaceuticals, United Therapeutics and AltaRex Corp. Additionally, she co-founded and served as Scientific Advisor at Advanced Immune Therapeutics, a company working to develop novel cancer therapeutics. She received her M.S. in Biology and Ph.D. in Immunology from the University of Bonn, Germany and a degree in Advanced Management Development from Boston University.

Positions